Community Acquired Pneumonia -- Background & Rationale to North American Guidelines

Table of Contents

Community Acquired PneumoniaBackground & Rationale to North American GuidelinesLionel Mandell MD FRCPCBrussels Belgium

Consider

Impact of the Disease

Issues to Reflect Upon

What Are The Important Etiologic Pathogens?

Etiology

S. pneumoniae

Atypical Pathogens

Outpatients Inpatients Nursing Home

Co-Pathogens

What’s Happening With Resistance?

S. PNEUMONIAE - 225 CENTRES ACROSS U.S. Jan ‘00-July ‘00

S. PNEUMONIAEJan ‘00-July ‘00

Impact of Resistance

What Are The Limitations of Current Diagnostic Methods?

PPT Slide

Sputum Gram’s Stain & Culture

What Are the Treatment Options?

Is Initial Antimicrobial Therapy Important?

A 5 Year Study of Severe CAP With Emphasis on Prognosis in Patients Admitted to an ICU

Factors Selected by Multivariate Analysis Independently Related to Mortality

Choosing Among the Options

FQ vs. Comparators

4 Studies Showing Statistically Significant Improvement For FQ vs. Comparators

Clinical Success Rates

PPT Slide

Demographics

Clinical Response

PPT Slide

Bacteriologic Response

Median Time to Defervescence

Other Outcomes

New Guidelines For CAP

Timelines

IDSA & CIDS-CTS

PPT Slide

PPT Slide

PPT Slide

PPT Slide

PPT Slide

PPT Slide

PPT Slide

PPT Slide

Are the Guidelines Validated?

PPT Slide

PPT Slide

Email: seminf@facm.ucl.ac.be

Home Page: http://www.md.ucl.ac.be/seminfect/resume.htm

Other information:
These slides are for information only. Do not make public use of them without the autorization of their author and of the organisers of the 'Séminaire de Pathologie Infectieuse'. Please, adress your request to <seminf@facm.ucl.ac.be>

Download presentation as PDF file